About Eyevistar®
A natural, standardized marigold flower extract derived from Tagetes erecta L., providing a defined combination of 20% lutein and 4% zeaxanthin.
Two macular carotenoids in one standardized ingredient
Eyevistar® is a natural, standardized marigold flower extract derived from Tagetes erecta L. It provides a defined combination of 20% lutein and 4% zeaxanthin, two naturally occurring xanthophyll carotenoids that are selectively concentrated in the macular region of the retina.
Lutein and zeaxanthin contribute to the formation of macular pigment. Within the eye, these carotenoids help filter high-energy blue light and neutralize reactive oxygen species, supporting the protection of retinal cells from phototoxic and oxidative stress. Because the human body cannot synthesize lutein and zeaxanthin, they must be obtained through dietary or supplemental sources.
Marigold flowers are recognized as an abundant commercial source of lutein and zeaxanthin. Eyevistar® combines both carotenoids in one standardized ingredient intended for eye-health and visual-performance nutraceutical formulations.
What makes Eyevistar® different?
Eyevistar® has been evaluated through complementary in-vitro and in-vivo preclinical studies focused on retinal oxidative stress, carotenoid bioavailability, A2E formation and lipofuscin accumulation.
In ARPE-19 human retinal pigment epithelial cells, Eyevistar® maintained high cell viability across tested concentrations and increased cell proliferation by 33.59%, 46.15% and 62.31% at concentrations of 125, 250 and 500 µg/mL, respectively. It also protected retinal cells from UV-A-induced oxidative injury and reduced the accumulation of A2E and lipofuscin.
In a high-fat-diet-induced retinal stress model, Eyevistar® was administered at 2.5, 5 and 10 mg/kg for 42 days. The study reported dose-dependent restoration of lutein and zeaxanthin in plasma and macular tissue, with the strongest response at 10 mg/kg. Histopathology and transmission electron microscopy findings indicated preservation of retinal architecture and reduced retinal lipofuscin accumulation.
A placebo-controlled human study evaluating lutein and zeaxanthin for macular pigment optical density, photostress recovery, glare disability and contrast sensitivity is ongoing. Until final results are available, Eyevistar® is described as preclinically studied rather than clinically proven.
- Standardization to 20% lutein and 4% zeaxanthin
- A dual-carotenoid composition derived from marigold
- Evaluation in ARPE-19 retinal pigment epithelial cells
- Evaluation in an in-vivo retinal oxidative and metabolic stress model
- Demonstrated deposition of lutein and zeaxanthin in plasma and macular tissue in animals
- Product-specific assessment of A2E and lipofuscin accumulation
- Manufacturing and registration by Star Hi Herbs Pvt. Ltd.
Designed for eye-health and visual-performance formulations
- Standardized marigold extract containing 20% lutein and 4% zeaxanthin
- Provides two key carotenoids naturally concentrated in the macula
- Supports retinal antioxidant protection
- Evaluated for protection against UV-A-induced retinal cell stress
- Studied for its effect on A2E and lipofuscin accumulation
- Demonstrated dose-dependent retinal carotenoid deposition in an animal model
- Suitable for eye-health and long-term visual-performance positioning
- Supported by product-specific in-vitro and in-vivo research
Documented product parameters
| Parameter | Eyevistar® details |
|---|---|
| Botanical source | Tagetes erecta L., marigold |
| Plant part used | Flowers |
| Standardized to | Lutein 20% and zeaxanthin 4% |
| Ingredient type | Standardized marigold extract |
| Appearance | To be confirmed from the commercial specification |
| Assay method | To be confirmed from the commercial specification |
| Solubility | To be confirmed |
| Research status | In-vitro and in-vivo preclinical evaluation |
| Human study status | Ongoing research |
Eye health, healthy ageing and visual performance
Eyevistar® is positioned for use in eye-health dietary supplements, healthy-ageing formulations and visual-performance nutraceutical products.
Potential dosage forms may include softgels, capsules, tablets, gummies and functional nutrition products. Final suitability for each format should be confirmed using the product's solubility, stability, carrier composition and processing data.
Request an Eyevistar® sample or specification sheet
Our ingredient team can provide samples, specifications and the research dossier for your formulation review.